Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease
Primary Purpose
Peripheral Arterial Disease, Hypercholesterolemia, Hypertension
Status
Unknown status
Phase
Phase 4
Locations
Spain
Study Type
Interventional
Intervention
Stepwise therapy for dyslipidemia, hypertension and diabetes
Dietary recommendations
Increase in physical activity
Smoking cessation
Sponsored by
About this trial
This is an interventional educational/counseling/training trial for Peripheral Arterial Disease
Eligibility Criteria
Inclusion Criteria: Arm-ankle index < 0.85 and > 0.40 in at least one leg Exclusion Criteria: Advanced peripheral arterial disease (arm-ankle index < 0.40 or amputation) Peripheral arterial disease of non-atherosclerotic origin (e.g. vasculitis) Heart failure (NYHA III or IV) End-stage renal disease Atrial fibrillation Active peptic ulcer disease Blood coagulation disorders Platelets disorders Cancer History of rhabdomyolysis Treatment with immunosuppressant agents (e.g. cyclosporine, glucocorticoids) Excessive intake of alcohol (> 280 gr/week) Institutionalized patients
Sites / Locations
- Hospital de Sabadell
Outcomes
Primary Outcome Measures
Lowering of LDL cholesterol concentrations and blood pressure levels (at 12 months). Increase in use of antiplatelet agents (at 12 months)
Secondary Outcome Measures
Decrease in basal glycaemia and HbA1c(only subjects with diabetes)
Lowering of serum triglycerides and total cholesterol.
Increase in serum HDL cholesterol
Improvement in cardiovascular risk (Framingham Score and UKPDS engine)
Weight reduction
Increase in physical activity
Changes in dietary intake
Smoking cessation
Improvement in health-related quality of life (SF-36)
Improvement of intermittent claudication
Improvement of arm-ankle index
Effect of control of cardiovascular risk factors on metabolic and inflammatory markers associated with cardiovascular disease
Changes in serum concentrations of hepatic enzymes
Changes in use of statins and fibrates
Changes in use of antihypertensive drugs and hypoglycemic agents
Cardiovascular events
All the above-mentioned primary and secondary outcomes will be evaluated at 12 months
Full Information
NCT ID
NCT00144937
First Posted
September 1, 2005
Last Updated
September 1, 2005
Sponsor
Hospital de Sabadell
Collaborators
Bristol-Myers Squibb
1. Study Identification
Unique Protocol Identification Number
NCT00144937
Brief Title
Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease
Official Title
A Randomized Controlled Trial Comparing Usual Care With a Multifactorial Intensified Intervention on Cardiovascular Risk Factors in Subjects With Arterial Peripheral Disease With and Without Diabetes. The Taulí Intervention Program (TIP).
Study Type
Interventional
2. Study Status
Record Verification Date
September 2005
Overall Recruitment Status
Unknown status
Study Start Date
March 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
August 2005 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Hospital de Sabadell
Collaborators
Bristol-Myers Squibb
4. Oversight
5. Study Description
Brief Summary
The purpose of this study was to evaluate whether an intensified multifactorial intervention program about cardiovascular risk factors in subjects with peripheral arterial disease (with and without diabetes mellitus), can improve the control of these factors (mainly hypercholesterolemia and hypertension) in relation to the habitual care
Detailed Description
Subjects with peripheral arterial disease show an increased cardiovascular risk. It is thought that improving control of cardiovascular risk factors (hypercholesterolemia, hypertension, diabetes, smoking) could be beneficial in reducing their cardiovascular risk. However, usual care of these subjects (mainly at primary care) is not associated with an optimal control of such cardiovascular risk factors. We hypothesise that an intensive multifactorial treatment in a Cardiovascular Risk Unit could improve control of these cardiovascular risk factors. To test this hypothesis we perform a controlled, randomized, open, parallel trial. Subjects are recruited at the Vascular Surgery Unit and are randomised into two groups: 1. usual care (control group); 2. intensive care (intervention group). Randomization is stratified for the presence/absence of diabetes mellitus and with the use of sealed envelopes. Patients assigned to receive usual care (general practitioner with the possibility of being referred to specialists) are compared to those assigned to undergo intensive multifactorial intervention. This intervention involves strict treatment goals (LDL-cholesterol < 100 mg/dl, blood pressure < 130/80, HbA1c < 7 %, no smoking) to be achieved through behavior modification (diet, physical activity, smoking cessation) and a stepwise introduction of pharmacologic therapy for hypercholesterolemia, hypertension and diabetes. This multifactorial intervention is overseen by a multidisciplinary team (endocrinologist, nurse, and dietitian) at the Hospital of Sabadell (Corporación Parc Taulí). The treatment goals are the same for the usual care group and general practitioners caring patients included in this study are informed of these strict treatment goals. Patients in the intensive-therapy receive 6 scheduled individual consultations in one year (baseline and 2,4, 6 and 9 months after their inclusion).Primary and secondary outcomes are evaluated at 12 months after their inclusion.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Peripheral Arterial Disease, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Smoking
7. Study Design
Primary Purpose
Educational/Counseling/Training
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Stepwise therapy for dyslipidemia, hypertension and diabetes
Intervention Type
Behavioral
Intervention Name(s)
Dietary recommendations
Intervention Type
Behavioral
Intervention Name(s)
Increase in physical activity
Intervention Type
Behavioral
Intervention Name(s)
Smoking cessation
Primary Outcome Measure Information:
Title
Lowering of LDL cholesterol concentrations and blood pressure levels (at 12 months). Increase in use of antiplatelet agents (at 12 months)
Secondary Outcome Measure Information:
Title
Decrease in basal glycaemia and HbA1c(only subjects with diabetes)
Title
Lowering of serum triglycerides and total cholesterol.
Title
Increase in serum HDL cholesterol
Title
Improvement in cardiovascular risk (Framingham Score and UKPDS engine)
Title
Weight reduction
Title
Increase in physical activity
Title
Changes in dietary intake
Title
Smoking cessation
Title
Improvement in health-related quality of life (SF-36)
Title
Improvement of intermittent claudication
Title
Improvement of arm-ankle index
Title
Effect of control of cardiovascular risk factors on metabolic and inflammatory markers associated with cardiovascular disease
Title
Changes in serum concentrations of hepatic enzymes
Title
Changes in use of statins and fibrates
Title
Changes in use of antihypertensive drugs and hypoglycemic agents
Title
Cardiovascular events
Title
All the above-mentioned primary and secondary outcomes will be evaluated at 12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Arm-ankle index < 0.85 and > 0.40 in at least one leg
Exclusion Criteria:
Advanced peripheral arterial disease (arm-ankle index < 0.40 or amputation)
Peripheral arterial disease of non-atherosclerotic origin (e.g. vasculitis)
Heart failure (NYHA III or IV)
End-stage renal disease
Atrial fibrillation
Active peptic ulcer disease
Blood coagulation disorders
Platelets disorders
Cancer
History of rhabdomyolysis
Treatment with immunosuppressant agents (e.g. cyclosporine, glucocorticoids)
Excessive intake of alcohol (> 280 gr/week)
Institutionalized patients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
José-Miguel González-Clemente, MD, PhD
Organizational Affiliation
Department of Diabetes, Endocrinology and Nutrition. Hospital de Sabadell
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dídac Mauricio, MD, PhD
Organizational Affiliation
Department of Diabetes, Endocrinology and Metabolism. Hospital de Sabadell
Official's Role
Study Chair
Facility Information:
Facility Name
Hospital de Sabadell
City
Sabadell
State/Province
Barcelona
ZIP/Postal Code
08208
Country
Spain
12. IPD Sharing Statement
Learn more about this trial
Multifactorial Intervention on Cardiovascular Risk Factors in Subjects With Peripheral Arterial Disease
We'll reach out to this number within 24 hrs